Long-term treatment of leiomyomas with gestrinone.
A prospective randomized study was conducted in 100 women with leiomyomas in order to evaluate the effect of gestrinone, a synthetic derivative of ethynil-nor-testosterone. Patients in group A received capsules containing 2.5 mg of gestrinone three times weekly orally. Those in group B received capsules containing 5.0 mg twice weekly, also orally. In group C, patients used by vaginal route tablets containing 5 mg of gestrinone three times weekly. Reduction in uterine volume occurred in all three groups of patients. Of patients who discontinued treatment at 6 months, uterine volume remained lower than pretreatment values in 89%, 18 months after discontinuation. Of those patients who discontinued at 1 year, uterine volume remained below pretreatment levels in 76% 1 year after discontinuation. In patients treated continuously for 24 months, mean uterine volume decreased from a mean 339 cm3 to 273 cm3, a statistically significant difference. The vaginal route showed statistically more significant volume decreases than the oral route for all treatment intervals.
Coutinho
E M
EM
Maternidade Climério de Oliveira, Federal University of Bahia, School of Medicine, Salvador, Brazil.
Gonçalves
M T
MT
D000282:Administration, Intravaginal; D000328:Adult; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D005260:Female; D005867:Gestrinone / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007889:Leiomyoma / Q000175:diagnosis / Q000188:drug therapy*; D009651:Norpregnatrienes / Q000627:therapeutic use*; D011247:Pregnancy; D011446:Prospective Studies; D011897:Random Allocation; D014463:Ultrasonography; D014594:Uterine Neoplasms / Q000175:diagnosis / Q000188:drug therapy*
D009651:Norpregnatrienes; D005867:Gestrinone